Description
Option Care Health: Expanding Acute and Chronic Care Platforms to Capture Long-Term Infusion Demand!
Option Care Health Inc., a prominent provider in home and alternate site infusion therapy, reported on its 2025 performance during a recent call, highlighting both accomplishments and challenges. For the year ended 2025, the company achieved a 13% increase in net revenue, totaling $5.6 billion, driven by growth in both acute and chronic therapies. Acute therapy revenue grew in the mid-teens while chronic therapies experienced low double-digit growth. The company maintained a strategic focus on building relationships with payers and expanding its referral network with specialty prescribers. This aligns with the industry’s broader shift towards cost-effective care in alternative settings. The rise in mobility and adoption of biosimilars, notably Stelara, presented challenges, leading to a 160-basis-point revenue headwind. On the profitability front, Option Care Health reported an adjusted EBITDA of $471 million, marking a 6% increase from the previous year. The EBITDA margin stood at 8.
